Printer Friendly

Daiichi Sankyo, Merck, Pfizer.

Daiichi Sankyo has entered into a clinical trial collaboration agreement with Merck KGaA and Pfizer to evaluate the combination of [fam-] trastuzumab deruxtecan (DS-8201), an investigational HER2 targeting antibody drug conjugate (ADC), in combination with the checkpoint inhibitor avelumab and/or an investigational Merck KGaA DNA damage response (DDR) inhibitor, in patients with HER2 expressing or mutated solid tumors.

A separate research collaboration to conduct preclinical studies evaluating [fam-] trastuzumab deruxtecan in combination with avelumab, the DDR inhibitor and other investigational compounds in Merck KGaA, Darmstadt, Germany's and Pfizer's pipelines is also underway.

"The collaboration is another milestone in our development strategy to maximize the potential of [fam-] trastuzumab deruxtecan for various F1ER2 expressing and mutated cancers in combination with immunotherapy and other agents with novel mechanisms of action," said Tom Held, vice president, head, Antibody Drug Conjugate Task Force, Oncology Research and Development, Daiichi Sankyo. "We look forward to working with Merck KGaA, Darmstadt, Germany and Pfizer to determine an appropriate combination strategy to help further improve outcomes for patients. In particular, we are enthusiastic about better understanding the potential of combining [fam-] trastuzumab deruxtecan with DNA damage response agents."

Under the agreement, Daiichi Sankyo will conduct a three-part Phase lb multicenter, open-label study to determine the safety and efficacy of [fam-] trastuzumab deruxtecan in combination with avelumab and/or a DDR inhibitor.

The primary endpoints of each part of the study are maximum tolerated dose, recommended expansion dose and objective response rate. Secondary endpoints include duration of response, disease control rate, progression-free survival, overall survival, time to response and key safety endpoints. The study is expected to enroll approximately 200 patients in the U.S., Europe and Asia.

COPYRIGHT 2018 Rodman Publishing
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2018 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Contract Pharma
Date:Nov 1, 2018
Previous Article:Catalent, Verastem.
Next Article:CANbridge, WuXi Biologics.

Terms of use | Privacy policy | Copyright © 2021 Farlex, Inc. | Feedback | For webmasters